Back to search results

Angiotensin-(1-7) for Cardiovascular Health in Aging

This study is looking at how a natural substance called Angiotensin-(1-7) might help improve heart and blood vessel health in older adults. As we age, our bodies can have increased activity in the sympathetic nervous system, which can affect blood pressure. Researchers want to see if Angiotensin-(1-7) can reduce this activity and improve how blood vessels work. You might be able to join if you are between 65 and 80 years old, have a healthy weight (BMI between 18.5 and 30 kg/m2), and have normal blood pressure without medication. The study will measure changes in nerve activity related to blood pressure after receiving Angiotensin-(1-7) or a placebo (saline). The current recruitment status is unclear.

Study design
This is a randomized, double-blind, placebo-controlled, crossover study, meaning participants will receive both Angiotensin-(1-7) and saline at different times, without knowing which they are getting. It plans to enroll 26 participants.
What's involved
You would have a screening visit, and if eligible, two study visits at the Clinical Research Center, each lasting about 4 hours. These visits involve intravenous infusions, blood samples, and measurements of blood pressure, heart rate, and nerve activity.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken at 110 minutes during the study visits. Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05301192

Angiotensin-(1-7) Cardiovascular Effects in Aging

Recruiting
EARLY_PHASE1Ages 65–80InterventionalBasic science
Milton S. Hershey Medical Center
~26 participants
Updated 2025-09-19 on ClinicalTrials.gov
What's tested:Angiotensin-(1-7)Saline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Muscle Sympathetic Nerve Burst Rate
Measured over 110 minutes

Conditions

Aging

Explore related trials

Aging

NCT05301192

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Amy Arnold, PhD · PRINCIPAL_INVESTIGATOR · Pennsylvania State University College of Medicine

Who to contact

Aimee Cauffman, RN
[email protected]
717-531-1617
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women of all races and ethnicities
Capable of giving informed consent
Fluent in written and spoken English
Age 65-80 years
Body mass index (BMI) between 18.5 and 30 kg/m2
Normotensive defined as seated blood pressure \<130/80 mmHg and without hypertensive medications
Satisfactory history and physical exam

Exclusion

Age \< 65 or \> 80 years
Women who are pregnant, nursing, or taking hormone replacement therapy
Decisional impairment
Prisoners
Current or recent (less than 6 months) recreational drug history or excessive alcohol abuse history (greater than 14 drinks per week)
Current smokers
Highly trained athletes
Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
Hypertension or history of serious cardiovascular disease (e.g., myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g., cerebral hemorrhage, stroke, transient ischemic attack).
History or presence of immunological or hematological disorders
Impaired hepatic function \[aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels \>2 times upper limit of normal range\]
Impaired renal function (serum creatinine \>2.0 mg/dl)
Anemia
Taking drugs known to influence sympathetic activity (e.g. serotonin-norepinephrine reuptake inhibitors, norepinephrine transporter inhibitors, stimulants).
Treatment with anticoagulants (e.g. warfarin)
Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month in the 1-month preceding the study)
Treatment with any investigational drug in the 1-month preceding the study
Known allergy or contraindication to angiotensin converting enzyme inhibitors or angiotensin receptor blockers, both of which increase endogenous angiotensin-(1-7) levels as part of their mechanism of action
Inability to give, or withdraw, informed consent

What this trial measures

  • Change in Muscle Sympathetic Nerve Burst Rate110 minutes

    Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion.